VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.
The Company’s lead oncology product candidate, VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed preliminary activity in an ”all comers“ Phase 1 trial as well as in three tumor-specific Phase 2 studies.... More >>
February 26, 2019
VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26
Oral Presentation Details: Title: MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases Presenter: Itzhak Mendel, PhD Date: Tuesday, February 26, 2019 Time: 8:00 – 11:00 AM MST Session: Myeloid Cells in Metabolic and Inflammatory Diseases Location: Eldorado Grand Ballroom Poster Presentation Details: Abstract: MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases Session title: Poster Session 2 Date: Tuesday, February 26, 2019 Time: 7:30 - 10:00 PM MST Poster #: 2028
For more information on the Keystone Symposium on Myeloid Cells, including a detailed program, refer to http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1553